• 1
    Kazatchkine MD, Kaveri SV. Immunomodulation of autoimmune and inflammatory diseases with intravenous immune globulin. N Engl J Med 2001;345: 747755.
  • 2
    Emmi L, Chiarini F. The role of intravenous immunoglobulin therapy in autoimmune and inflammatory disorders. Neurol Sci 2002;23(Suppl. 1):S1S8.
  • 3
    Larroche C, Chanseaud Y, Garcia de la Pena-Lefebvre, Mouthon L. Mechanisms of intravenous immunoglobulin action in the treatment of autoimmune disorders. BioDrugs 2002;16: 4755.
  • 4
    Sewell WA, Jolles S. Immunomodulatory action of intravenous immunoglobulin. Immunology 2002;107: 387393.
  • 5
    Pollack M. Antibody activity against Pseudomonas aeruginosa in immune globulins prepared for intravenous use in humans. J Infect Dis 1983;147: 10901098.
  • 6
    Fischer GW, Hunter KW, Hemming VG, Wilson SR. Functional antibacterial activity of a human intravenous immunoglobulin preparation: In vitro and in vivo studies. Vox Sang 1983;44: 296299.
  • 7
    Fischer GW, Hemming VG, Gloser HP et al. Polyvalent group-B streptococcal immune globulin for intravenous administration – overview. Rev Infect Dis 1990;12: S483S491.
  • 8
    Givner LB, Baker CJ. Pooled human IgG hyperimmune for type-III group-B Streptococci – Evaluation against multiple strains invitro and in experimental disease. J Infect Dis 1991;163: 11411145.
  • 9
    Cunningham-Rundles C, Hanson LA, Hitzig WH et al. Appropriate uses of human immunoglobulin in clinical practice: Memorandum from an UIS/WHO meeting. Bull WHO 1982;60: 4347.
  • 10
    Norrby-Teglund A, Basma H, Andersson J, McGeer A, Low DE, Kotb M. Varying titers of neutralizing antibodies to streptococcal superantigens in different preparations of normal polyspecific immunoglobulin G: Implications for therapeutic efficacy. Clin Infect Dis 1998;26: 631638.
  • 11
    Lamari F, Anastassiou ED, Tsegenidis T, Dimitracopoulos G, Karamanos NK. An enzyme immunoassay to determine the levels of specific antibodies toward bacterial surface antigens in human immunoglobulin preparations and blood serum. J Pharm Biomed Anal 1999;20: 913920.
  • 12
    Matejtschuk P, Chidwick K, Prince A, More JE, Goldblatt D. A direct comparison of the antigen-specific antibody profiles of intravenous immunoglobulins derived from US and UK donor plasma. Vox Sanguinis 2002;83: 1722.
  • 13
    Terness P, Opelz G. Natural anti-immunoglobulin autoantibodies: Irrelevant by-products or immunoregulatory molecules? Int Arch Allergy Immunol 1998;115: 270277.
  • 14
    Cukrowska B, Sinkora J, Mandel L et al. Thymic B cells of pig fetuses and germ-free pigs spontaneously produce IgM, IgG and IgA: detection by ELISPOT method. Immunology 1996;87: 487492.
  • 15
    Cukrowska B, Sinkora J, Reháková Z et al. Isotype and antibody specificity of spontaneously formed immunoglobulins in pig fetuses and germ-free piglets: Production by CDinline image B cells. Immunology 1996;88: 611617.
  • 16
    Baccala R, Vo Quang T, Gilbert M, Ternynck T, Avrameas S. Two murine natural polyreactive autoantibodies are encoded by nonmutated germ-line genes. PNAS 1989;86: 46244628.
  • 17
    Berneman A, Guilbert B, Eschrich S, Avrameas S. IgG auto and polyreactivities of normal human sera. Mol Immunol 1993;30: 14991510.
  • 18
    Prabhakar BS, Saegusa J, Onodera T, Notkins AL. Lymphocytes capable of making autoantibodies that react with multiple organs are a sommon feature of the normal B cell repertoire. J Immunol 1984;133: 28152820.
  • 19
    Ochsenbein AF, Fehr T, Lutz C et al. Control of early viral and bacterial distribution and disease by natural antibodies. Science 1999;286: 21562159.
  • 20
    Guinamard R, Okigaki M, Schlessinger J, Ravetch JV. Absence of marginal zone B cells in Pyk-2-deficient mice defines their role in the humoral response. Nat Immunol 2000;1: 3136.
  • 21
    Fagarasan S, Honjo T. T-independent immune response: new aspects of B cell biology. Science 2000;290: 8991.
  • 22
    Lutz HU. How pre-existing, germline-derived antibodies and complement may help induce a primary immune response to nonself. Scand J Immunol 1999;49: 224228.
  • 23
    Thornton BP, Vetvicka V, Ross GD. Natural antibody and complement-mediated antigen processing and presentation by B lymphocytes. J Immunol 1994;152: 17271737.
  • 24
    Ohteki T, Hessel A, Bachmann MF et al. Identification of a cross-reactive self ligand in virus-mediated autoimmunity. J Immunol 1999;29: 28862896.
  • 25
    Leung DYM, Meissner HC, Fulton DR, Murray DL, Kotzin BL, Schlievert PM. Toxic shock syndrome toxin-secreting Staphylococcus aureus in Kawasaki syndrome. Lancet 1993;342: 13851388.
  • 26
    Horwitz MS, Sarvetnick N. Viruses, host responses, and autoimmunity. Immunol Rev 1999;169: 241253.
  • 27
    Rossi F, Kazatchkine MD. Antiidiotypes against autoantibodies in pooled normal human polyspecific Ig. J Immunol 1989;143: 41044109.
  • 28
    Sultan Y, Kazatchkine MD, Maisonneuve P, Nydegger UE. Anti-idiotypic suppression of autoantibodies to factor VIII (antihaemophilic factor) by high dose intravenous gammaglobulin. Lancet 1984;II: 765768.
  • 29
    Lundkvist I, Van Doorn PA, Vermeulen M, Brand A. Spontaneous recovery from the Guillain-Barre syndrome is associated with anti-idiotypic antibodies recognizing a cross-reactive idiotype on anti-neuroblastoma cell line antibodies. Clin Immunol Immunopathol 1993;67: 192198.
  • 30
    Buchwald B, Ahangari R, Weishaupt A, Toyka KV. Intravenous immunoglobulins neutralize blocking antibodies in Guillain-Barré syndrome. Ann Neurol 2002;51: 673680.
  • 31
    Van Doorn PA, Rossi F, Brand A, Van Lint M, Vermeulen M, Kazatchkine MD. On the mechanism of high-dose intravenous immunoglobulin treatment of patients with chronic inflammatory demyelinating polyneuropathy. J Neuroimmunol 1990;29: 5764.
  • 32
    Dwyer DS, Bradley RJ, Urquart CK, Kearney JF. Naturally occurring anti-idiotypic antibodies in myasthenia gravis patients. Nature 1983;301: 611614.
  • 33
    Rossi F, Jayne DRW, Lockwood CM, Kazatchkine MD. Anti-idiotypes against anti-neutrophil cytoplasmic antigen autoantibodies in normal human polyspecific IgG for therapeutic use and in the remission sera of patients with systemic vasculitis. Clin Exp Immunol 1991;83: 298303.
  • 34
    Dietrich G, Kazatchkine MD. Normal immunoglobulin G (IgG) for therapeutic use (intravenous Ig) contains anti-idiotypic specificies against an immunodominant, disease-associated, cross-reactive idiotype of human anti-thyroglobulin autoantibodies. J Clin Invest 1990;85: 620625.
  • 35
    Berchtold P, Dale GL, Tani P, McMillan R. Inhibition of autoantibody binding to platelet glycoprotein IIb/IIIa by anti-idiotypic antibodies in intravenous gammaglobulin. Blood 1989;74: 24142417.
  • 36
    Marchalonis JJ, Kaymaz H, Dedeoglu F, Schluter SF, Yocum DE, Edmundson AB. Human autoantibodies reactive with synthetic autoantigens from T-cell receptor beta-chain. PNAS 1992;89: 33253329.
  • 37
    Klaesson S, Ringden O, Markling L, Remberger M, Lundkvist I. Immune modulatory effects of immunoglobulins on cell-mediated immune responses in vitro. Scand J Immunol 1993;38: 477484.
  • 38
    Coggeshall KM. Inhibitory signaling by B cell FcγRIIb. Curr Opin Immunol 1998;10: 306312.
  • 39
    Hurez V, Kaveri SV, Mouhoub A et al. Anti-CD4 activity of normal human immunoglobulin G for therapeutic use. (Intravenous immunoglobulin, IVIg). Ther Immunol 1994;1: 269277.
  • 40
    Kaveri S, Vassilev T, Hurez V et al. Antibodies to a conserved region of HLA class I molecules, capable of modulating CD8 T cell-mediated function, are present in pooled normal immunoglobulin for therapeutic use. J Clin Invest 1996;97: 865869.
  • 41
    Phan TG, Wong RC, Crotty K, Adelstein S. Toxic epidermal necrolysis in acquired immunodeficiency syndrome treated with intravenous gammaglobulin. Aus J Dermatol 1999;40: 153157.
  • 42
    Andresen M, Boghero Y, Molgo M, Dougnao A, Diaz O. Toxic epidermal necrolysis. Therapy in ICU with intravenous immunoglobulins in a case. Rev Med Chil 2000;128: 13431348.
  • 43
    Magina S, Lisboa C, Goncalves E, Conceicao F, Leal V, Mesquita-Guimaraes J. A case of toxic epidermal necrolysis treated with intravenous immunoglobin. Br J Dermatol 2000;142: 191192.
  • 44
    Paquet P, Jacob E, Damas P, Pierard GE. Treatment of drug-induced toxic epidermal necrolysis (Lyell's syndrome) with intravenous human immunoglobulins. Burns 2001;27: 652655.
  • 45
    Viard I, Wehrli P, Bullani R et al. Inhibition of toxic epidermal necrolysis by blockade of CD95 with human intravenous immunoglobulin. Science 1998;282: 490493.
  • 46
    Prins C, Kerdel FA, Padilla RS et al. Treatment of toxic epidermal necrolysis with high-dose intravenous immunoglobulins: multicenter retrospective analysis of 48 consecutive cases. Arch Dermatol 2003;139: 2632.
  • 47
    Trautmann A, Akdis M, Schmid-Grendelmeier P et al. Targeting keratinocyte apoptosis in the treatment of atopic dermatitis and allergic contact dermatitis. J Allergy Clin Immunol 2001;108: 839846.
  • 48
    Prasad NKA, Papoff G, Zeuner A et al. Therapeutic preparations of normal polyspecific IgG (IVIg) induce apoptosis in human lymphocytes and monocytes: a novel mechanism of action of IVIg involving the Fas apoptotic pathway. J Immunol 1998;161: 37813790.
  • 49
    Varambally S, Prasad N, Bonnin E et al. Phosphorylation of Bcl-2 and mitochondrial changes are associated with apoptosis of lymphoblastoid cells induced by normal immunoglobulin G. Biochem Biophys Res Commun 1999;264: 896901.
  • 50
    Simon HU, Yousefi S, Dommann-Scherrer CC et al. Expansion of cytokine-producing CD4-CD8- T cells associated with abnormal Fas expression and hypereosinophilia. J Exp Med 1996;183: 10711082.
  • 51
    Daigle I, Yousefi S, Colonna M, Green DR, Simon HU. Death receptors bind SHP-1 and block cytokine-induced anti-apoptotic signaling in neutrophils. Nat Med 2002;8: 6167.
  • 52
    Hebestreit H, Yousefi S, Balatti I et al. Expression and function of the fas receptor on human blood and tissue eosinophils. Eur J Immunol 1996;26: 17751780.
  • 53
    Bendtzen K, Svenson M, Hansen M. Autoantibodies to cytokines in IVIG. J Rheumatol 1993;20: 21762177.
  • 54
    Abe Y, Horiuchi A, Miyake M, Kimura S. Anti-cytokine nature of natural human immunoglobulin: one possible mechanism of the clinical effect of intravenous immunoglobulin therapy. Immunol Rev 1994;139: 519.
  • 55
    Ross C, Svenson M, Hansen MB, Veijlsgaard GL, Bendtzen K. Specific autoantibodies directed against interferon-α in pharmaceutically prepared human immunoglobulin preparations. J Interferon Res 1994;14: 159160.
  • 56
    Emmenegger U, Frey U, Reimers A et al. Hyperferritinemia as indicator for intravenous immunogloblin treatment in reactive macrophage activation syndromes. Am J Hematol 2001;68: 410.
  • 57
    Farber CM, Crusiaux A, Schandene L et al. Tumor necrosis factor and intravenous gammaglobulins in common variable immunodeficiency. Clin Immunol Immunopathol 1994;72: 233236.
  • 58
    Aukrust P, Froland SS, Liabakk NB et al. Release of cytokines, soluble cytokine receptors, and interleukin-1 receptor antagonist after intravenous immunoglobulin administration in vivo. Blood 1994;84: 21362143.
  • 59
    Wolf HH, Davies SV, Borte M et al. Efficacy, tolerability, safety and pharmacokinetics of a nanofiltered intravenous immunoglobulin: studies in patients with immune thrombocytopenic purpura and primary immunodeficiencies. Vox Sang 2003;84: 4553.
  • 60
    Roux KH, Tankersley DL. A view of the human idiotypic repertoire – electron microscopic and immunologic analyses of spontaneous idiotype-anti-idiotype dimers in pooled human IgG. J Immunol 1990;144: 13871395.
  • 61
    Tankersley DL. Dimer formation in immunoglobulin preparations and speculations on the mechanism of action of intravenous immune globulin in autoimmune diseases. Immunol Rev 1994;139: 159172.
  • 62
    Teeling JL, Jansen-Hendriks T, Kuijpers TW et al. Therapeutic efficacy of intravenous immunoglobulin preparations depends on the immunoglobulin G dimers: studies in experimental immune thrombocytopenia. Blood 2001;98: 10951099.
  • 63
    Teeling JL, Bleeker WK, Rigter GM, Van Rooijen N, Kuijpers TW, Hack CE. Intravenous immunoglobulin preparations induce mild activation of neutrophils in vivo via triggering of macrophages – studies in a rat model. Br J Haematol 2001;112: 10311040.
  • 64
    Pricop L, Redecha P, Teillaud JL et al. Differential modulation of stimulatory and inhibitory Fcgamma receptors on human monocytes by Th1 and Th2 cytokines. J Immunol 2001;166: 531537.
  • 65
    Sharief MK, Ingram DA, Swash M, Thompson EJ. I.v. immunoglobulin reduces circulating proinflammatory cytokines in Guillain-Barré syndrome. Neurology 1999;52: 18331838.
  • 66
    Samuelsson A, Towers TL, Ravetch JV. Anti-inflammatory activity of IVIG mediated through the inhibitory Fc receptor. Science 2001;291: 484486.
  • 67
    Davis RS, Wang YH, Kubagawa H, Cooper MD. Identification of a family of Fc receptor homologs with preferential B cell expression. PNAS 2001;98: 97729777.
  • 68
    Hatzivassiliou G, Miller I, Takizawa J et al. IRTA1 and IRTA2, novel immunoglobulin superfamily receptors expressed in B cells and involved in chromosome 1q21 abnormalities in B cell malignancy. Immunity 2001;14: 277289.
  • 69
    Yu Z, Lennon VA. Mechanism of intravenous immune globulin therapy in antibody-mediated autoimmune diseases. N Engl J Med 1999;340: 227228.
  • 70
    Hansen RJ, Balthasar JP. Intravenous immunoglobulin mediates an increase in anti-platelet antibody clearance via the FcRn receptor. Thromb Haemost 2002;88: 898899.
  • 71
    Basta M, Kirshbom P, Frank MM, Fries LF. Mechanism of therapeutic effect of high-dose intravenous immunoglobulin. Attenuation of acute, complement-dependent immune damage in a guinea pig model. J Clin Invest 1989;84: 19741981.
  • 72
    Lutz HU, Stammler P, Jelezarova E, Nater M, Späth PJ. High doses of immunoglobulin G attenuate immune aggregate-mediated complement activation by enhancing physiologic cleavage of C3b in C3bn -IgG complexes. Blood 1996;88: 184193.
  • 73
    Basta M, Dalakas MC. High-dose intravenous immunoglobulin exerts its beneficial effect in patients with dermatomyositis by blocking endomysial deposition of activated complement fragments. J Clin Invest 1994;94: 17291735.
  • 74
    Lutz HU, Stammler P, Späth PJ, Hess-Schmid M, Trüeb RM, Jelezarova E. High dose pooled human IgG (IVIG) has a complement attenuating effect in vivo in an inflammatory disease. Mol Immunol 1998;35: 368A.
  • 75
    Newburger JW, Takahashi M, Beiser AS et al. A single intravenous infusion of gamma-globulin as compared with four infusions in the treatment of acute Kawasaki syndrome. N Engl J Med 1991;324: 16331639.
  • 76
    Newburger JW, Takahashi M, Burns JC et al. The treatment of Kawasaki syndrome with intravenous gamma globulin. N Engl J Med 1986;315: 341347.
  • 77
    Hughes RAC, Swan AV, Cornblath DR, Hartung HP. Randomised trial of plasma exchange, intravenous immunoglobulin, and combined treatment in Guillain-Barré syndrome. Plasma Exchange/Sandoglobulin Guillain-Barré Syndrome Trial Group. Lancet 1997;349: 225230.
  • 78
    Blanchette V, Imbach P, Andrew M et al. Randomised trial of intravenous immunoglobulin G, intravenous anti-D, and oral prednisone in childhood acute immune thrombocytopenic purpura. Lancet 1994;344: 703707.
  • 79
    Hughes RA, Bensa S, Willison H et al. Randomized controlled trial of intravenous immunoglobulin versus oral prednisolone in chronic inflammatory demyelinating polyradiculoneuropathy. Ann Neurol 2001;50: 195201.
  • 80
    Léger JM, Chassande B, Musset L, Meininger V, Bouche P, Baumann N. Intravenous immunoglobulin therapy in multifocal motor neuropathy: a double-blind, placebo-controlled study. Brain 2001;124: 145153.
  • 81
    Dalakas MC, Illa I, Dambrosia JM et al. A controlled trial of high-dose intravenous immune globulin infusions as treatment for dermatomyositis. N Engl J Med 1993;329: 19932000.
  • 82
    Arsura EL, Bick A, Brunner NG, Namba T, Grob D. High-dose intravenous immunoglobulin in the management of Myasthenia gravis. Arch Intern Med 1986;146: 13651368.
  • 83
    Jayne DR, Chapel H, Adu D et al. Intravenous immunoglobulin for ANCA-associated systemic vasculitis with persistent disease activity. QJM 2000;93: 433439.
  • 84
    Francioni C, Fioravanti A, Gelli R, Megale F, Marcolongo R. Long-term treatment with i.v. immunoglobulin in the therapy of systemic lupus erythematosus. Recent Prog Med 1993;84: 679686.
  • 85
    Levy Y, Sherer Y, Ahmed A et al. A study of 20 SLE patients with intravenous immunoglobulin – clinical and serologic response. Lupus 1999;8: 705712.
  • 86
    Papo T. Polyvalent intravenous immunoglobulins in systemic lupus. Rev Med Intern 1999;20(Suppl. 4):414S418S.
  • 87
    Jolles S. A review of high-dose intravenous immunoglobulin (hdIVIg) in the treatment of the autoimmune blistering disorders. Clin Exp Dermatol 2001;26: 127131.
  • 88
    O'Donnell BF, Barr RM, Kobza-Black A et al. Intravenous immunoglobulin in autoimmune chronic urticaria. Br J Dermatol 1998;138: 101106.
  • 89
    Trent JT, Kirsner RS, Romanelli P, Kerdel FA. Analysis of intravenous immunoglobulin for the treatment of toxic epidermal necrolysis using SCORTEN: The University of Miami Experience. Arch Dermatol 2003;139: 3943.
  • 90
    Harman KE, Whittam LR, Wakelin SH, Black MM. Severe, refractory epidermolysis bullosa acquisita complicated by an oesophageal stricture responding to intravenous immune globulin. Br J Dermatol 1998;139: 11261127.
  • 91
    Stella M, Cassano P, Bollero D, Clemente A, Giorio G. Toxic epidermal necrolysis treated with intravenous high-dose immunoglobulins: our experience. Dermatology 2001;203: 4549.
  • 92
    Tristani-Firouzi P, Petersen MJ, Saffle JR, Morris SE, Zone JJ. Treatment of toxic epidermal necrolysis with intravenous immunoglobulin in children. J Am Acad Dermatol 2002;47: 548552.
  • 93
    Oehling AG, Akdis CA, Schapowal A, Blaser K, Schmitz M, Simon HU. Suppression of the immune system by oral glucocorticoid therapy in bronchial asthma. Allergy 1997;52: 144154.
  • 94
    Sigman K, Ghibu F, Sommerville W et al. Intravenous immunoglobulin inhibits IgE production in human B lymphocytes. J Allergy Clin Immunol 1998;102: 421427.
  • 95
    Landwehr LP, Jeppson JD, Katlan MG et al. Benefits of high-dose i.v. immunoglobulin in patients with severe steroid-dependent asthma. Chest 1998;114: 13491356.
  • 96
    Rabinovitch N, Gelfand EW, Leung DY. The role of immunoglobulin therapy in allergic diseases. Allergy 1999;54: 662668.
  • 97
    Hamilos DL, Christensen J. Treatment of Churg-Strauss syndrome with high-dose intravenous immunoglobulin. J Allergy Clin Immunol 1991;88: 823824.
  • 98
    Gelfand EW, Landwehr LP, Esterl B, Mazer B. Intravenous immune globulin: an alternative therapy in steroid-dependent allergic diseases. Clin Exp Immunol 1996;104: 6166.